Preparation method and application of platelet lysate rich in extracellular vesicles
Through intermittent ultrasound lysis and HEPES buffer washing, platelet lysate rich in extracellular vesicles was prepared, which solved the problem of destroying cell membranes and safety hazards when platelets were activated in the prior art, and achieved high content of extracellular vesicles The preparation of vesicles has significant biological activity and safety advantages.
Patent Information
- Application Number
- CN202411490973.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-24
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-10-24
AI Technical Summary
The existing preparation methods for platelet lysate are prone to destroy the cell membrane and release substances when activate platelets. The external addition of thrombin or calcium ions poses a safety hazard and fail to effectively increase the content of extracellular vesicles.
Using intermittent ultrasonic lysis method, platelet lysate is prepared rich in extracellular vesicles by sonicating the platelet resuspension in an ice-water bath, combined with HEPES buffer containing ACD anticoagulant, and washing it with HEPES buffer to prevent exogenous addition of coagulation. Enzyme or collagen, easy and safe.
The prepared platelet lysate has a high content of extracellular vesicles, a small diameter, a high content of biologically active proteins, and no external addition of thrombin or calcium ions, providing a safer and more effective platelet derivative product with significant wound promotion Healing and cell proliferation potential.
Smart Images

Figure CN118995597A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of molecular biology and medical technology, and specifically relates to a preparation method of a platelet lysate rich in extracellular vesicles and an application thereof. Background Art
[0002] Platelets contain three main types of granules: α granules, dense granules, and lysozyme granules. α granules are the largest and most abundant secretory granules in platelets, and contain important growth factors in the process of blood vessel and tissue formation. When activated, platelets release various platelet-derived cytokines, including platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), transforming growth factor (TGF-β), and vascular endothelial growth factor (VEGF). These growth factors can stimulate the proliferation of fibroblasts, smooth muscle cells, and osteoblasts, and can attract a variety of cell components to participate in the repair of damaged tissues. Platelet lysate (PL) is a platelet-derived product obtained by artificially releasing the abundant active factors in platelets. The preparation of platelet lysate is currently mainly carried out by repeated freezing and thawing, followed by several methods such as adding thrombin or calcium ions. Thrombin and calcium ions are physiological activators of platelets and are also effective activators. However, thrombin is mainly derived from cattle. For safety reasons, people have been looking for a better activation method. Repeated freezing and thawing will not only destroy the cell membrane and release active products, but also cause different degrees of damage to these substances, which mainly depends on the number of freeze-thaw cycles. Extracellular vesicles (EVs) are membrane vesicles released from the plasma membrane (microcapsules or microparticles) or intracellular bodies (exosomes). They are produced after platelet activation and play an important role in inflammation, cancer progression, natural defense, tissue repair, thrombosis and neurobiology. Platelet-derived EVs (PEVs) transport different cargoes (such as RNA, lipids and proteins), which can be transferred to recipient cells. The therapeutic potential of PEVs is being explored, and they can promote coagulation and angiogenesis in different animal models of bleeding and trauma. In addition, PEVs have been found to be beneficial for the treatment of chronic injuries and trauma. At present, in the process of preparing platelet lysate, few consider increasing the content of extracellular vesicles (EVs) at the same time. Summary of the invention
[0003] Therefore, based on the above background, the present invention provides a method for preparing a platelet lysate rich in extracellular vesicles and its application. The platelet lysate prepared by the present invention has a high content of extracellular vesicles, which can provide direction for the further development and application of platelet lysate.
[0004] The technical solution of the present invention is: A method for preparing a platelet lysate rich in extracellular vesicles comprises the following steps: S1: Take whole blood, add it to the anticoagulant tube, remove red blood cells, and prepare concentrated platelets; S2: washing and resuspending platelets with HEPES buffer containing ACD anticoagulant, wherein the mass concentration of ACD is 0.3%; S3: intermittently ultrasonically lyse the platelet resuspension in step S2 under an ice water bath; S4: Centrifuge the lysate from step S3 at 4° C. and collect the supernatant as the platelet lysate rich in extracellular vesicles.
[0005] Furthermore, the conditions for intermittent ultrasonic lysis in step S3 are: ultrasonic treatment for 5 seconds, stop for 5 seconds, cycle 30 times, and ultrasonic power 100W.
[0006] Furthermore, the operation of removing red blood cells and preparing concentrated platelets in step S1 is as follows: 1) Centrifuge the plasma at room temperature and take the plasma and buffy coat; 2) Centrifuge the plasma and buffy coat from step 1) at room temperature and take the precipitate.
[0007] Furthermore, the concentration of platelets in the resuspension prepared in step S2 is 1000×10 9 / L.
[0008] Based on the same inventive concept, the present invention provides a platelet lysate rich in extracellular vesicles prepared by the above-mentioned preparation method.
[0009] Based on the same inventive concept, the present invention applies the platelet lysate rich in extracellular vesicles prepared by the above preparation method to cell culture.
[0010] Furthermore, the cells include human umbilical vein endothelial cells.
[0011] Based on the same inventive concept, the present invention applies the platelet lysate rich in extracellular vesicles prepared by the above preparation method to prepare extracellular vesicles.
[0012] Furthermore, the preparation of the extracellular vesicles is performed as follows: ① Take the platelet lysate rich in extracellular vesicles, centrifuge it, and take the supernatant; ② Centrifuge the supernatant obtained in step 1) again and take the precipitate.
[0013] Based on the same inventive concept, the present invention provides an extracellular vesicle prepared by using the platelet lysate super-enriched in extracellular vesicles prepared as described above.
[0014] Furthermore, the extracellular vesicles can be used to prepare preparations that can promote wound healing.
[0015] The above technical solution has the following beneficial effects: 1) In the process of preparing platelet lysate by intermittent ultrasonic lysis, no exogenous addition of biochemical components such as thrombin, collagen or Ca ions is required, which is simpler and safer.
[0016] 2) The present invention sets reasonable ultrasonic process parameters, so that the platelet lysate prepared is not only rich in various factors (such as bFGF, VEGF, PDGF-BB, etc., and IL-6, IL-15, IL-17 and INF-γ) but also has a high content of bioactive proteins.
[0017] The extracellular vesicles in the platelet lysate prepared by the present invention not only have a high content but also a small diameter. The average diameter of the extracellular vesicles can be as low as 79.9 nm. The proportion of exosomes is relatively large, and the transmembrane protein CD9 of the extracellular vesicles is highly expressed and CD81 is lowly expressed.
[0018] 3) The platelet lysate prepared by the present invention can be concentrated and purified to prepare extracellular vesicle products, which can provide new ideas and directions for the preparation of platelet extracellular vesicle-related products. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 This is a bar graph showing the contents of bFGF, VEGF and PDGF-BB in platelet lysates prepared by three different methods according to the embodiments of the present invention.
[0020] Figure 2 This is a bar graph showing the contents of IL-6, IL-15, IL-17 and INF-γ in platelet lysates prepared by three different methods according to the embodiments of the present invention.
[0021] Figure 3 The live cell densities at 24h and 48h respectively when platelet lysates prepared by three different methods were used for cell culture in the embodiments of the present invention.
[0022] Figure 4 Diameter distribution diagram of extracellular vesicles in platelet lysates prepared by three different methods according to the embodiments of the present invention.
[0023] Figure 5 This is a graph showing the relative content of protein factors in the extracellular vesicles prepared in accordance with an embodiment of the present invention.
[0024] Figure 6 This is an expression diagram of the transmembrane protein content in the lysate prepared in the example of the present invention. DETAILED DESCRIPTION
[0025] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with its embodiments; it should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0026] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.
[0027] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.
[0028] The equipment used in the following examples: JY98-IID ultrasonic cell pulverizer; Mindray fully automatic blood cell analyzer, BC-20.
[0029] Example 1: A method for preparing a platelet lysate rich in extracellular vesicles, comprising the following steps: S1: Take whole blood from a healthy person without any disease into an anticoagulant tube, remove red blood cells, and prepare concentrated platelets; The specific operations of this step are: 1) Centrifuge the plasma in the anticoagulant tube at room temperature: 300g*20min, and take the plasma and buffy coat; 2) Centrifuge the plasma and buffy coat layer from step 1) at room temperature: 900g*15min, and take the precipitate.
[0030] S2: Wash and resuspend platelets in HEPES buffer containing ACD anticoagulant. The concentration of platelets in the resuspension prepared in this step is 1000×10 9 / L; the mass concentration of the ACD is about 0.3%.
[0031] S3: intermittent ultrasonic lysis of the platelet resuspension in step S2 under an ice-water bath; the conditions of the intermittent ultrasonic lysis in this step are: ultrasonic treatment for 5 seconds, stop for 5 seconds, cycle 30 times, and ultrasonic power 100w.
[0032] S4: Centrifuge the lysate from step S3 at 4°C: 400g*20min, and collect the supernatant as the platelet lysate rich in extracellular vesicles.
[0033] Example 2: In this example, the preparation method of Example 1, the repeated freeze-thaw method, and the external thrombin method are respectively used to prepare platelet lysate, wherein the platelet lysate prepared in Example 1 is referred to as SPL, the platelet lysate prepared by the repeated freeze-thaw method is referred to as FTPL, and the platelet lysate prepared by the external thrombin method is referred to as TPL.
[0034] The operation of the repeated freeze-thaw method is as follows: Collect blood from healthy people without any disease into anticoagulation tubes, remove red blood cells and prepare concentrated platelets; The platelets were washed with HEPES buffer containing ACD anticoagulant, placed at -80°C for 12 hours and incubated in a water bath at 37°C for 30 minutes, repeated three times, centrifuged at 4°C for 20 minutes at 4000 g, and the supernatant was collected as the platelet lysate prepared by repeated freezing and thawing; the mass concentration of ACD was about 0.3%; The operation of the thrombin addition method is as follows: Collect blood from healthy people without any disease into anticoagulation tubes, remove red blood cells and prepare concentrated platelets; The platelets were washed with HEPES buffer containing ACD anticoagulant, and a mixture of thrombin and calcium ions (finally 100u / ml thrombin and 22.8mM calcium ions) was added, incubated in a 37°C water bath for 30min, centrifuged at 4°C for 20min at 4000g, and the supernatant was collected as the platelet activation solution prepared with thrombin. The mass concentration of ACD is about 0.3%; The whole blood of the platelet lysate prepared by the three methods in this example comes from the same human body.
[0035] Next, the Luminex detection technology was used to detect the content of specific active factors in the lysate prepared above. Figure 1 and Figure 2 As shown, Figure 1 It is obvious that SPL contains a higher content of bFGF, and a relatively high content of VEGF and PDGF-BB. Among them, basic fibroblast growth factor (bFGF) promotes the proliferation and division of almost all cells related to trauma, such as fibroblasts, vascular endothelial cells, smooth muscle cells, epithelial cells, chondrocytes and nerve cells. This may suggest that SPL may have a more significant effect on wound healing.
[0036] Figure 2 As shown: SPL contains high levels of IL-6, IL-15, IL-17 and INF-γ, which may indicate that SPL is more effective in improving the body's resistance to infection.
[0037] Example 3: Human umbilical vein endothelial cells (HUVEC) were treated with the lysates prepared by the three preparation methods in Example 2, specifically: HUVECs were seeded into 96-well plates, with about 3,000 cells per well. When the cell density reached about 70%, DMEM culture medium containing the platelet lysate prepared above was added (the mass concentration of the platelet lysate added was 10%). After culturing for 24 h and 48 h, the cell viability was detected according to the instructions of the CCK8 kit. The results are shown in Figure 3 .Depend on Figure 3 It is obvious that the cells in the SPL group showed a stronger proliferation-promoting trend after 24h of HUVEC treatment, and the effect of promoting cell proliferation in the SPL group was more significant after 48h of HUVEC treatment.
[0038] Example 4: This example further analyzes extracellular vesicles.
[0039] The three platelet lysates prepared by the three preparation methods in Example 2 were centrifuged at 10,000 xg, 4°C for 45 min, respectively, and the supernatant was taken. The supernatant was then centrifuged at 100,000 xg, 4°C for 70 min, the precipitate was taken, and the precipitate was resuspended with PBS to obtain an extracellular vesicle suspension.
[0040] The diameter and distribution of extracellular vesicles were characterized by a nanoparticle size analyzer (NTA), the protein concentration of the extracellular vesicles was measured by the BCA method, and the specific markers of the extracellular vesicles were characterized by fluorescent labeling of CD9, CD63, and CD81. Figures 4 to 6 shown.
[0041] Depend on Figure 4 The results showed that the average diameter of extracellular vesicles in the SPL group was the smallest, which was 79.9 nm, while the average diameters of extracellular vesicles in the TPL group and FTPL group were 82.7 nm and 87.4 nm, respectively. The content of extracellular vesicles in the SPL group was relatively richer, with a concentration of up to 3.81×10 9 / ml.
[0042] Considering the important role of protein factors in extracellular vesicles in their biology, the protein / extracellular vesicle content of the three groups of extracellular vesicles was compared. Figure 5 It can be seen that the protein / extracellular vesicle ratio of the SPL group was 0.37, while that of the TPL group and FTPL group was 0.23 and 0.11, respectively. This indicates that the extracellular vesicles of the SPL group contain more proteins, that is, there may be more protein active factors, which will have greater potential for the treatment of diseases.
[0043] Depend on Figure 6It can be seen that after fluorescent labeling of CD9, CD63, and CD81, the SPL group highly expressed CD9 (about 16.3%) and lowly expressed CD81 (about 6.6%), which was similar to the FTPL group, CD9 (about 17.7%), CD81 (about 6.8%), while the TPL group was the opposite, CD9 (about 5.7%), CD81 (about 20.6%), which may indicate that the platelet vesicles produced by platelet lysis and the extracellular vesicles produced by thrombin activation have different functional subpopulation classifications.
[0044] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for preparing a platelet lysate rich in extracellular vesicles, characterized in that: S1: Take whole blood, add it to the anticoagulant tube, remove red blood cells, and prepare concentrated platelets; S2: washing and resuspending platelets with HEPES buffer containing ACD anticoagulant, wherein the mass concentration of ACD is 0.3%; S3: intermittently ultrasonically lyse the platelet resuspension in step S2 under an ice water bath; S4: The lysate from step S3 is centrifuged at 4° C. and the supernatant is collected as the platelet lysate rich in extracellular vesicles.
2. The method for preparing a platelet lysate rich in extracellular vesicles according to claim 1, characterized in that: The conditions of intermittent ultrasonic lysis in step S3 are: ultrasonic treatment for 5 seconds, stop for 5 seconds, cycle 30 times, and ultrasonic power 100W.
3. The method for preparing a platelet lysate rich in extracellular vesicles according to claim 1, characterized in that: The operation of removing red blood cells and preparing concentrated platelets in step S1 is as follows: 1) Centrifuge the plasma at room temperature and take the plasma and buffy coat; 2) Centrifuge the plasma and buffy coat layer from step 1) at room temperature and take the precipitate.
4. The method for preparing a platelet lysate rich in extracellular vesicles according to claim 3, characterized in that: The concentration of platelets in the resuspension prepared in step S2 is 1000×10 9 / L.
5. A platelet lysate rich in extracellular vesicles prepared by the preparation method according to any one of claims 1 to 4.
6. Use of the platelet lysate rich in extracellular vesicles according to claim 5 in cell culture.
7. The use according to claim 6, characterized in that: The cells include human umbilical vein endothelial cells.
8. Use of the platelet lysate rich in extracellular vesicles according to claim 5 in preparing extracellular vesicles.
9. The use according to claim 8, characterized in that: The preparation of the extracellular vesicles is as follows: ① Take the platelet lysate rich in extracellular vesicles, centrifuge it, and take the supernatant; ② Centrifuge the supernatant obtained in step 1) again and take the precipitate.
Citation Information
Patent Citations
Platelet lysate and preparation method and application thereof
CN114058576A
Method for preparing platelet lysate and uses for increasing female pregnancy rate
JP2021109875A
Platelet-derived composition and method for producing the same
JP2024100157A
Particulate lyophilized platelet lysate compositions
US20180163172A1
Platelet derived extracellular vesicles
US20230149468A1
Cited By
Platelet-rich plasma capable of resisting aging and promoting tissue repair and regeneration as well as preparation method and application of platelet-rich plasma
CN120437172A
